Almirall SA (ALMRY)
10.53
0.00 (0.00%)
USD |
OTCM |
Oct 29, 16:00
Almirall Enterprise Value : 2.097B for Oct. 29, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 29, 2026 | 2.097B |
| October 28, 2026 | 2.097B |
| October 27, 2026 | 2.097B |
| October 26, 2026 | 2.097B |
| October 23, 2026 | 2.097B |
| October 22, 2026 | 2.097B |
| October 21, 2026 | 2.097B |
| October 20, 2026 | 2.097B |
| October 19, 2026 | 2.097B |
| October 16, 2026 | 2.097B |
| October 15, 2026 | 2.097B |
| October 14, 2026 | 2.097B |
| October 13, 2026 | 2.097B |
| October 12, 2026 | 2.097B |
| October 09, 2026 | 2.097B |
| October 08, 2026 | 2.097B |
| October 07, 2026 | 2.097B |
| October 06, 2026 | 2.785B |
| October 05, 2026 | 2.914B |
| October 02, 2026 | 2.914B |
| October 01, 2026 | 2.914B |
| September 30, 2026 | 2.914B |
| September 29, 2026 | 2.914B |
| September 28, 2026 | 2.914B |
| September 25, 2026 | 2.914B |
| Date | Value |
|---|---|
| September 24, 2026 | 2.914B |
| September 23, 2026 | 2.914B |
| September 22, 2026 | 2.914B |
| September 21, 2026 | 2.914B |
| September 18, 2026 | 2.914B |
| September 17, 2026 | 2.914B |
| September 16, 2026 | 2.914B |
| September 15, 2026 | 2.914B |
| September 14, 2026 | 2.914B |
| September 11, 2026 | 2.914B |
| September 10, 2026 | 2.914B |
| September 09, 2026 | 2.914B |
| September 08, 2026 | 2.914B |
| September 04, 2026 | 2.914B |
| September 03, 2026 | 2.914B |
| September 02, 2026 | 2.914B |
| September 01, 2026 | 2.914B |
| August 31, 2026 | 2.914B |
| August 28, 2026 | 2.914B |
| August 27, 2026 | 2.914B |
| August 26, 2026 | 2.914B |
| August 25, 2026 | 2.914B |
| August 24, 2026 | 2.914B |
| August 21, 2026 | 2.914B |
| August 20, 2026 | 2.914B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Laboratorios Farmaceúticos Rovi SA | 3.431B |
| AstraZeneca PLC | 567.22B |
| ANI Pharmaceuticals, Inc. | 1.915B |
| Corcept Therapeutics, Inc. | 8.977B |
| Veru, Inc. | 14.91M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 28.25M |
| Revenue (Quarterly) | 365.79M |
| Total Expenses (Quarterly) | 337.53M |
| Gross Profit Margin (Quarterly) | 64.43% |
| Profit Margin (Quarterly) | 7.72% |
| Earnings Yield | 3.02% |
| Operating Earnings Yield | 4.90% |
| Normalized Earnings Yield | 2.948 |